Trevena Announces Completion of Phase 1 Study for TRV045, Novel S1P Receptor Modulator

November 9, 2022

https://www.globenewswire.com/news-release/2022/11/09/2551838/0/en/Trevena-Announces-Completion-of-Phase-1-Study-for-TRV045-Novel-S1P-Receptor-Modulator.html

TRV045 demonstrated a favorable tolerability profile with no reported SAEs and no lymphopenia

Nonclinical study showed anti-inflammatory signaling, suggesting a potential disease-modifying effect of TRV045 in the treatment of epilepsy, based on astrocyte cell culture study

Read more at globenewswire.com

Related news for (TRVN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.